Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1/2 Active not recruiting 249 enrolled Molecular Partners AG

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Timeline

Start: 2022-12-29
Primary completion: 2026-05-29
Completion: 2027-05

Publications

Bianchi M, Reichen C, Croset A, Fischer S, Eggenschwiler A, Grubler Y, Marpakwar R, Looser T, Spitzli P, Herzog C, Villemagne D, Schiegg D, Abduli L, Iss C, Neculcea A, Franchini M, Lekishvili T, Ragusa S, Zitt C, Kaufmann Y, Auge A, Hanggi M, Ali W, Frasconi TM, Wullschleger S, Schlegel I, Matzner M, Luthi U, Schlereth B, Dawson KM, Kirkin V, Ochsenbein AF, Grimm S, Reschke N, Riether C, Steiner D, Leupin N, Goubier A. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. Cancer Immunol Res. 2024 Jul 2;12(7):921-943. doi: 10.1158/2326-6066.CIR-23-0692.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitidine	Other / unclassified	—	Subcutaneous
Subject	MP0533	Protein / enzyme biologic	—	Intravenous
Subject	Venetoclax	Small molecule	—	Oral
Background	Obinutuzumab	Monoclonal antibody	—	—

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Summary

Timeline

Publications

Drugs

Indications